argenx SE
ARGXDrugs in Pipeline
13
Phase 3 Programs
9
Upcoming Catalysts
9
Next Catalyst
May 1, 2026
4wMarket Overview
Stock performance and key metrics
10 upcoming, 2 past
Efgartigimod IV
Generalized Myasthenia Gravis
ARGX-113
Pemphigus Vulgaris
Efgartigimod PH20 SC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
EFG PH20 SC
Active Idiopathic Inflammatory Myopathy
IVIG (Intravenous Immunoglobulin)
Multifocal Motor Neuropathy (MMN)
Efgartigimod
Postural Orthostatic Tachycardia Syndrome
empasiprubart
Chronic Inflammatory Demyelinating Polyneuropathy
Prednisone
Bullous Pemphigoid
Empasiprubart IV
Chronic Inflammatory Demyelinating Polyneuropathy
ARGX-119
Amyotrophic Lateral Sclerosis
ARGX-117
Multifocal Motor Neuropathy
efgartigimod PH20 SC in stage B
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ARGX-119 IV
Spinal Muscular Atrophy (SMA)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efgartigimod IV | Phase 3 | Generalized Myasthenia Gravis | - | - |
ARGX-113 | Phase 3 | Pemphigus Vulgaris | - | - |
Efgartigimod PH20 SC | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
EFG PH20 SC | Phase 3 | Active Idiopathic Inflammatory Myopathy | - | - |
IVIG (Intravenous Immunoglobulin) | Phase 3 | Multifocal Motor Neuropathy (MMN) | - | - |
Efgartigimod | Phase 3 | Postural Orthostatic Tachycardia Syndrome | - | - |
empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Prednisone | Phase 3 | Bullous Pemphigoid | - | - |
Empasiprubart IV | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
ARGX-119 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
ARGX-117 | Phase 2 | Multifocal Motor Neuropathy | - | - |
efgartigimod PH20 SC in stage B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
ARGX-119 IV | Phase 2 | Spinal Muscular Atrophy (SMA) | - | - |